A detailed history of Wealth Effects LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Wealth Effects LLC holds 160,025 shares of ARWR stock, worth $3.14 Million. This represents 1.22% of its overall portfolio holdings.

Number of Shares
160,025
Previous 159,600 0.27%
Holding current value
$3.14 Million
Previous $4.15 Million 25.31%
% of portfolio
1.22%
Previous 1.71%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$19.36 - $29.54 $8,228 - $12,554
425 Added 0.27%
160,025 $3.1 Million
Q2 2024

Aug 02, 2024

SELL
$21.87 - $28.24 $106,288 - $137,246
-4,860 Reduced 2.96%
159,600 $4.15 Million
Q1 2024

Apr 22, 2024

BUY
$27.21 - $39.48 $71,018 - $103,042
2,610 Added 1.61%
164,460 $4.7 Million
Q4 2023

Jan 29, 2024

SELL
$21.2 - $31.03 $61,480 - $89,987
-2,900 Reduced 1.76%
161,850 $4.95 Million
Q3 2023

Oct 16, 2023

BUY
$26.2 - $36.08 $18,340 - $25,256
700 Added 0.43%
164,750 $4.43 Million
Q2 2023

Jul 18, 2023

BUY
$25.16 - $41.38 $182,158 - $299,591
7,240 Added 4.62%
164,050 $5.85 Million
Q1 2023

May 04, 2023

BUY
$23.68 - $38.51 $28,179 - $45,826
1,190 Added 0.76%
156,810 $3.98 Million
Q4 2022

Feb 02, 2023

SELL
$28.0 - $40.56 $28,000 - $40,560
-1,000 Reduced 0.64%
155,620 $6.31 Million
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $88,890 - $144,930
3,000 Added 1.95%
156,620 $5.18 Million
Q2 2022

Aug 03, 2022

BUY
$27.79 - $50.61 $94,486 - $172,074
3,400 Added 2.26%
153,620 $5.41 Million
Q1 2022

May 16, 2022

BUY
$39.62 - $69.97 $168,781 - $298,072
4,260 Added 2.92%
150,220 $6.91 Million
Q4 2021

Feb 09, 2022

BUY
$58.09 - $82.51 $8.48 Million - $12 Million
145,960 New
145,960 $9.68 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Wealth Effects LLC Portfolio

Follow Wealth Effects LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealth Effects LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealth Effects LLC with notifications on news.